TITLE:
Sustained Remission with Mogamulizumab in Peripheral T Cell Lymphoma with Aberrant CD20 Expression: Case Report and Literature Review
AUTHORS:
Kentaro Fukushima, Hiroshi Sata, Masami Imakita, Takahiro Karasuno
KEYWORDS:
Peripheral T Cell Lymphoma, CD20, PTCL-NOS, Aberrant Expression, Mogamulizumab
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.9 No.3,
March
6,
2018
ABSTRACT: A 82-year-old man presented with an enlarged
multiple superficial lymph nodes. The histological diagnosis of lymph node was
peripheral T cell lymphoma, not otherwise specified (PTCL-NOS), with an
aberrant expression of CD20. Generally, PTCL lacks B cell antigen such as CD19
or CD20, however, rare cases have been reported in the literature that showed
PTCL patients expressing the B cell antigens. It is considered that the
prognosis of CD20 positive PTCL is poor, however, standard therapy has not been
established. He was treated with eight cycles of CHOP regimen, but the
enlargement of a part of lymph nodes still remained. Recently, it is reported
that C-C Chemokine receptor type 4 (CCR4) is known to be expressed about 50%
case of PTCL and CCR4 target therapy is effective. Our case was positive for
CCR4 so mogamulizumab (anti-CCR4 antibody) was administered. Consequently,
dramatic response was obtained and its combination of these therapy resulted in
complete remission for 24 months. This is the first case of sustained remission
by administration of mogamulizumab against CCR4/CD20 double positive PTCL. This
strategy may be benefit to obtain the good prognosis.